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Abstract
Background: Disruption of endogenous circadian rhythms has been shown to increase the risk of developing type 2
diabetes, suggesting that circadian genes might play a role in determining disease susceptibility. We present the results of a
pilot study investigating the association between type 2 diabetes and selected single nucleotide polymorphisms (SNPs) in/
near nine circadian genes. The variants were chosen based on their previously reported association with prostate cancer, a
disease that has been suggested to have a genetic link with type 2 diabetes through a number of shared inherited risk
determinants.
Methodology/Principal Findings: The pilot study was performed using two genetically homogeneous Punjabi cohorts, one
resident in the United Kingdom and one indigenous to Pakistan. Subjects with (N=1732) and without (N=1780) type 2
diabetes were genotyped for thirteen circadian variants using a competitive allele-specific polymerase chain reaction
method. Associations between the SNPs and type 2 diabetes were investigated using logistic regression. The results were
also combined with in silico data from other South Asian datasets (SAT2D consortium) and white European cohorts
(DIAGRAM+) using meta-analysis. The rs7602358G allele near PER2 was negatively associated with type 2 diabetes in our
Punjabi cohorts (combined odds ratio [OR]=0.75 [0.66–0.86], p=3.18610
25), while the BMAL1 rs11022775T allele was
associated with an increased risk of the disease (combined OR=1.22 [1.07–1.39], p=0.003). Neither of these associations
was replicated in the SAT2D or DIAGRAM+ datasets, however. Meta-analysis of all the cohorts identified disease associations
with two variants, rs2292912 in CRY2 and rs12315175 near CRY1, although statistical significance was nominal (combined
OR=1.05 [1.01–1.08], p=0.008 and OR=0.95 [0.91–0.99], p=0.015 respectively).
Conclusions/significance: None of the selected circadian gene variants was associated with type 2 diabetes with study-
wide significance after meta-analysis. The nominal association observed with the CRY2 SNP, however, complements
previous findings and confirms a role for this locus in disease susceptibility.
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Introduction
Accumulating evidence suggests that dysregulation of the
circadian clock plays an important role in glucose homeostasis
and the development of type 2 diabetes. Cross-sectional and
prospective studies have shown that voluntary sleep curtailment to
6 hours or less per day is associated with increased fasting glucose
levels, hyperinsulinaemia and reduced insulin sensitivity, leading
to an increased risk of diabetes [1,2]. Laboratory-imposed
circadian desynchrony, resulting in misalignment between behav-
ioural cycles (such as sleep/wake and fasting/feeding) and
endogenous circadian rhythm, has also been shown to result in
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e32670increased postprandial glucose and insulin levels, increased mean
arterial blood pressure and decreased leptin levels [3]. These
metabolic disturbances could explain the increased risk of diabetes,
obesity and cardiovascular disease observed in shift-workers [4,5].
Circadian rhythms are controlled and maintained by transcrip-
tion-translation-based networks of positive and negative feedback
loops that oscillate with 24-hour rhythmicity [6]. A recent study in
mice showed that mutations in the genes encoding the CLOCK
and BMAL1 transcription factors resulted in impaired glucose
tolerance, reduced insulin secretion and defects in islet develop-
ment, while ablation of the endogenous pancreatic clock resulted
in the development of diabetes [7]. Variants of circadian genes,
such as MTNR1B, CRY2, PER3, PER2 and BMAL1, have recently
been implicated as determinants of fasting glucose levels and/or
diabetes risk in humans [8–12], while single nucleotide polymor-
phisms (SNPs) in the CLOCK and PER2 genes were reported to be
associated with measures of obesity [13,14]. Further investigations
of circadian genes as risk markers for metabolic disease are
therefore warranted.
We aimed to investigate the role of circadian gene variants as
susceptibility determinants for type 2 diabetes. Before embarking
on a comprehensive tag SNP analysis, however, we carried out a
pilot study of selected variants chosen on the basis of their
previously reported association with prostate cancer, another
condition where risk has been shown to be modified by circadian
misalignment [15]. The relationship between type 2 diabetes and
prostate cancer is controversial. Although a number of studies
have suggested that diabetic men appear to be less prone to
prostate cancer than non-diabetic men (relative risk=0.84 from a
recent meta-analysis [16]), this negative correlation between the
diseases has not been observed in all populations. Despite this
epidemiological inconsistency, there is compelling evidence of a
genetic link between the two diseases. Variants in HNF1B, UCP2,
SLC2A2, IGF2BP2, TCF7L2 and CAPN10 have been shown to
predispose to type 2 diabetes and protect against prostate cancer
or vice versa [17,18]. A recent study also reported an inverse
association between the risk of prostate cancer and a genetic risk
score for type 2 diabetes [19], although a subsequent study of a
subset of 17 diabetes-associated SNPs in a multiethnic cohort
found no evidence of an impact on prostate cancer risk [20]. The
JAZF1 gene has been implicated in both disorders, although the
cancer-protective and diabetes-predisposing effects are mediated
by different SNPs [17]. Similarly, independent association signals
for the two diseases have been identified in the THADA gene by
genome-wide association studies (GWAS) [21,22]. A recent report
by Zhu et al [23] suggested that twelve variants in, or close to, nine
circadian-related genes were associated with overall prostate
cancer risk, or risk of more or less aggressive disease. The aim
of our pilot study was to determine whether these SNPs also
influence the risk of type 2 diabetes.
Materials and Methods
Ethics Statement
Informed written consent was obtained from all participants and
the study was approved by the Birmingham East, North and
Solihull Research Ethics Committee (for participants resident in
the United Kingdom) and the Baqai Institute of Diabetology and
Endocrinology Institutional Review Board (for participants
resident in Pakistan).
Study Participants
The study was performed using two populations of South Asian
origin. UK-resident subjects (892 with type 2 diabetes, 471
normoglycaemic individuals) were recruited from Birmingham
and Coventry as part of the United Kingdom Asian Diabetes
Study (UKADS) [24] (UKADS registered clinical trial number;
ISRCTN38297969). Pakistan-based subjects (840 with type 2
diabetes, 1309 normoglycaemic individuals) were recruited from
the Mirpur region of Azad Kashmir (Diabetes Genetics in Pakistan
study, DGP). All individuals were of Punjabi ancestry and
originated predominantly from Mirpur. Diagnosis of type 2
diabetes was established using World Health Organisation criteria
[25]. Normoglycaemia was defined as random blood glucose
,7mmol/l in the UKADS control subjects and fasting whole
blood glucose #5.6mmol/l in the DGP control subjects. Details of
the study subjects have been published previously [26].
Genotyping
The subjects (N=3512) were genotyped for selected circadian
gene variants using the KASPar method (KBiosciences, Hoddes-
don, UK). The twelve SNPs previously associated with prostate
cancer were investigated (CLOCK, rs11133373; BMAL1,
rs7950226; PER1, rs885747 and rs2289591; PER2, rs7602358;
PER3, rs1012477; CRY1, rs12315175; CRY2, rs2292912; CSNK1E,
rs1534891; NPAS2, rs1369481, rs895521 and rs17024926)[23]. In
addition we also genotyped for BMAL1 rs11022775, as this has
previously been shown to be part of a susceptibility haplotype for
type 2 diabetes along with rs7950226 [12]. For all SNPs,
genotyping success rates were .96% and error rates in 384
duplicate samples were ,0.6%.
Statistical Analysis
Statistical analysis was performed using STATA IC (version
10.1)(Stata Corporation, College Station, TX, USA). Genotype
frequencies for each SNP were checked for deviation from Hardy-
Weinberg equilibrium in the normoglycaemic subjects using an
exact test. The association between SNPs and type 2 diabetes was
tested using logistic regression, adjusting for age and sex. The
indigenous and migrant populations were analysed separately in
the first instance; odds ratio (OR) values were then combined using
inverse variance weighted meta-analysis, implemented in ME-
TAN. A study-wide significance threshold of p,0.0039 was
applied to the analysis of the 13 SNPs in these datasets. To
improve sample size and get a truer picture of the impact of the
SNPs on disease risk, meta-analysis was used to combine data from
the pilot study with summary statistics from the GWA phases of
the expanded DIAbetes Genetics Replication And Meta-analysis
(DIAGRAM+) study [27] and the South Asian Type 2 Diabetes
(SAT2D) study [28]. The DIAGRAM+ cohort comprised 8,130
cases with type 2 diabetes and 38,987 control subjects of white
European ancestry, while the SAT2D dataset consisted of 5,561
South Asian individuals with type 2 diabetes and 14,458
ethnically-matched control subjects. Heterogeneity of OR values
between the UKADS and DGP study populations, and between
the combined UKADS/DGP dataset, SAT2D and DIAGRAM+
cohorts, was assessed using Cochran’s Q statistic. Haplotype
analysis for the BMAL1 locus was performed using a logistic
regression framework implemented in PLINK [29].
Results
The clinical characteristics of the UKADS/DGP study subjects
are shown in Table S1. None of the studied SNPs deviated
significantly from Hardy-Weinberg equilibrium in the control
groups from these cohorts after correction for the number of tests
performed. Table 1 shows the OR values (with 95% confidence
intervals) and significance values for the association of type 2
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e32670Figure 1. Association of 13 circadian gene SNPs with type 2 diabetes. Forest plot showing the association of 13 circadian gene SNPs with
type 2 diabetes in South Asian (UKADS/DGP and SAT2D) and white European (DIAGRAM+) cohorts.
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populations, along with the DIAGRAM+ and SAT2D cohorts.
OR values did not differ significantly between the indigenous and
migrant Punjabi populations in our study; therefore results are
presented for the combined UKADS/DGP dataset. Sex-specific
analysis of this cohort showed no significant differences in OR
values between males and females (Table S2).
Two of the variants were associated with type 2 diabetes in the
UKADS/DGP cohort at a study-wide significant level (Table 1).
The minor allele (T) of BMAL1 rs11022775 was associated with
susceptibility to the disease (p=0.003). The rs11022775T/
rs7950226A BMAL1 haplotype was also nominally associated with
an increased risk of diabetes in this cohort before correction for
multiple testing (p=0.007); this effect appeared to be driven by the
rs11022775 SNP. In contrast, the minor allele (G) of rs7602358
near the PER2 locus appeared to confer protection against type 2
diabetes in both the UKADS (p=0.003) and DGP (p=0.004)
datasets (combined cohort, p=3.18610
25). Neither of these
observations was confirmed in the SAT2D or DIAGRAM+
datasets, however. The BMAL1 rs11022775 SNP was nominally
associated with disease in the DIAGRAM+ cohort, but disease risk
appeared to be conferred by the C allele, not T as seen in
UKADS/DGP. No evidence of an association with rs7602358 was
seen in the DIAGRAM+ or SAT2D datasets. In the latter cohort,
two NPAS2 SNPs (rs1369481 and rs17024926) were associated
with type 2 diabetes, the former with a p value of 3.78610
24, but
this was not replicated in the UKADS/DGP or DIAGRAM+
datasets (Table 1).
Meta-analysis of all the datasets failed to confirm the disease
associations with the BMAL1 and PER2 variants. In contrast, type
2 diabetes was associated with rs12315175, close to the CRY1
gene, and rs2292912, located in the CRY2 gene (Table 1 and
Figure 1), although statistical significance was nominal in both
cases.
Discussion
The pilot study of 13 circadian gene variants in two populations
of Punjabi ancestry suggested a significantly protective influence of
the G allele of the rs7602358 SNP, located upstream of the PER2
locus (OR=0.75, p=3.18610
25). The association was consistent
in independently ascertained indigenous and migrant populations,
with almost identical effect sizes (DGP, OR=0.77; UKADS,
OR=0.73), and was observed in both males and females (Table
S2). Furthermore this SNP was more strongly associated with type
2 diabetes in the combined UKADS/DGP cohorts than most of
the currently validated type 2 diabetes risk determinants, with the
exception of the TCF7L2 rs7902346 variant [26], leading us to
believe that the association might be genuine. This was not
confirmed by the analysis of the DIAGRAM+ and SAT2D
cohorts, however, which showed no evidence of a role for
rs7602358 in disease risk. These findings suggest that we have
either identified a false positive association or picked up a variant
with a population-specific effect. It should be noted that the South
Asians included in the SAT2D study were from different ethnic
subgroups to those in the UKADS/DGP cohorts and this could
contribute to the discrepancy between the observed effect sizes.
The inconsistency in results could not be attributed to differences
in minor allele frequency for rs7602358 as it was similar in all the
datasets (Table S3).
The BMAL1 locus was associated with type 2 diabetes in our
Punjabi populations, albeit with borderline significance. Our
findings differed from those reported previously by Woon et al
[12], who showed that the rs7950226A/rs11022775C haplotype
was associated with an increased risk of diabetes in British families,
with the former variant independently more strongly associated
than the latter. In contrast, disease susceptibility in the UKADS/
DGP cohort was associated with rs7950226A/rs11022775T and
this effect appeared to be mediated entirely through rs11022775T.
The borderline associations with BMAL1 variants seen in the
UKADS/DGP and DIAGRAM+ datasets and the inconsistency
between the results suggest that they are likely to be false positives,
a conclusion borne out by the lack of association with either SNP
in the meta-analysis.
The analysis of the SAT2D data showed two potentially
interesting associations with the NPAS2 locus, with the rs1369481
variant achieving a reasonable level of significance
(p=3.78610
24). As for the SNPs described above, however, this
was not replicated in either of the other datasets and no consistent
direction of effect was observed.
Although meta-analysis of the datasets did not confirm disease
associations with the PER2 and BMAL1 variants, it did provide
nominal evidence of associations with CRY2 rs2292912 and
CRY1 rs12315175. The former SNP is located ,4.6 kb from
rs11605924, which was reported to be associated with type 2
diabetes in the MAGIC study (p=1.7610
24)[9], with a similar
effect size (OR=1.04) to that seen for rs2292912 in the current
meta-analysis (OR=1.05). These two variants are not in strong
linkage disequilibrium (LD) (r
2=0.3 in HapMap Data Release 27;
www.hapmap.ncbi.nlm.nih.gov), suggesting that there might be
two independent association signals for type 2 diabetes at this
locus. The association with rs12315175 near CRY1 is a novel
finding. Interestingly recent studies in mice have suggested a role
for Cry1 in glucose homeostasis; hepatic overexpression of the
protein was shown to lower blood glucose concentrations and
improve insulin sensitivity in insulin-resistant db/db mice [30],
while transgenic mice expressing a mutant form of Cry1 developed
hyperglycaemia associated with an early-onset insulin-secretory
defect [31]. The role of CRY1 in human diabetes may therefore
warrant further investigation.
It is interesting to note that the variants displaying significant
disease associations in individual populations in our study appear
to have opposite directions of effect on type 2 diabetes and prostate
cancer; that is the minor alleles of the CRY2 and NPAS2 variants
that appear to increase the risk of diabetes in one or more of our
datasets are associated with a decreased risk of prostate cancer in
the study of Zhu et al [23], while the putative diabetes-protective
alleles near PER2 and CRY1 appear to confer an increased risk of
prostate cancer. These findings are consistent with the inverse
disease relationship reported by meta-analysis of epidemiological
data [16]. It should be noted, however, that none of the prostate
cancer associations described by Zhu et al [23] achieved genome-
wide significance and the variants are yet to be confirmed as
genuine risk determinants for the disease.
As our pilot study investigated only selected circadian variants,
we cannot exclude the possibility that other SNPs at these loci
have an influence on disease susceptibility. It is unlikely that such
an influence would be major, however, as we would expect this to
have been picked up by the genome-wide association analysis of
the DIAGRAM+ and SAT2D datasets [27,28]. Nevertheless it is
possible that variants of these genes have a more modest effect,
which did not reach the threshold for follow-up in these studies.
In conclusion our study has confirmed the association between
type 2 diabetes and variants of the CRY2 gene and suggested a
potential role for the CRY1 gene in disease development. Together
with previous reports of associations between fasting glucose/
diabetes and the MTNR1B and CRY2 loci [8,9], our data support a
Circadian Genes and Risk of Type 2 Diabetes
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homeostasis.
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